TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

CTI BioPharma – 8/25/2021

CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing and commercializing Pacritinib, its product candidate…

Dynavax Technologies Corp – 8/6/2020

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  Dynavax is also developing CpG 1018 as an advanced vaccine…

Dynavax Technologies Corp – 5/22/2020

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines. Dynavax’s sole marketed product, HEPLISAV-B, was approved in November 2017 and launched in February 2018 for the prevention of infection caused by all known subtypes of Hepatitis B virus in adults age 18 years or older. Dynavax is…

Vir Biotechnology, Inc. – 7/8/2020

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The Company has assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA. The Company’s current development pipeline consists of product candidates targeting severe…

Icosavax, Inc. – 7/28/2021

Icosavax (the “Company”) is a biotechnology company developing virus-like particle (VLP) vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The Company’s VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, which could induce broad, robust and durable protection against the specific targeted virus. Icosavax’s lead vaccine candidate, IVX-A12, is a…

Cue Health, Inc. – 9/23/2021

Cue Health Inc. (“Cue Health” or the “Company”) is a health technology company that has developed a platform consisting of the following hardware and software components: (1) the Cue Health Monitoring System, made up of a portable, durable and reusable reader, a single-use test cartridge, and a sample collection wand, (2) the Cue Data and Innovation Layer, with cloud-based data…

BioCryst Pharmaceuticals – 12/7/2020

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years…

Gritstone bio, Inc. – 9/16/2021

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can…

Looking for other transactions?

Browse our Transactions Library for our latest updates.

See More